CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed
Drug / intervention
encainide +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00000526
NCT00000526Phase 3Completed
CompareCT.gov

Cardiac Arrhythmia Suppression Trial (CAST)

National Heart, Lung, and Blood Institute (NHLBI)·interventional·Posted Oct 28, 1999·Updated May 6, 2016

In Brief

A Phase 3 clinical trial evaluating encainide, flecainide, and 1 other intervention for Cardiovascular Diseases and 7 related conditions. Completed.

Detailed Summary

To determine whether drug treatment of asymptomatic ventricular arrhythmias in post-myocardial infarction patients reduced the incidence of sudden cardiac death and total mortality.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCardiovascular Diseases, Coronary Disease, Death, Sudden, Cardiac, Heart Arrest, Heart Diseases, Myocardial Infarction, Myocardial Ischemia, Ventricular Arrhythmia
Countries--
Collaborators--

Timeline

Phase 3CompletedFinished
198619871988198919901991199219931994199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedOct 28, 1999
Enrollment StartAug 1, 1986
Study CompletionMar 1, 1998
TodayJul 2, 2026
Posted 26.7 years ago

Interventions

encainidedrug

flecainidedrug

moricizinedrug